Background. Cerebral ischemic stroke is one of the severe diseases with a pathological condition that leads to nerve cell dysfunction with seldom available therapy options. Currently, there are few proven effective treatments available for improving cerebral ischemic stroke outcome. However, recently, there is increasing evidence that inhibition of histone deacetylase (HDAC) activity exerts a strong protective effect in in vivo and vitro models of ischemic stroke. Review Summary. HDAC is a posttranslational modification that is negatively regulated by histone acetyltransferase (HATS) and histone deacetylase. Based on function and DNA sequence similarity, histone deacetylases (HDACs) are organized into four different subclasses (I-IV). Modifications of histones play a crucial role in cerebral ischemic affair development after translation by modulating disrupted acetylation homeostasis. HDAC inhibitors (HDACi) mainly exert neuroprotective effects by enhancing histone and nonhistone acetylation levels and enhancing gene expression and protein modification functions. This article reviews HDAC and its inhibitors, hoping to find meaningful therapeutic targets. Conclusions. HDAC may be a new biological target for cerebral ischemic stroke. Future drug development targeting HDAC may make it a potentially effective anticerebral ischemic stroke drug.

中文翻译：

---

更新组蛋白去乙酰化酶及其抑制剂在脑缺血性卒中潜在治疗中的策略。

背景。脑缺血性中风是一种严重的疾病，其病理状态会导致神经细胞功能障碍，很少有治疗选择。目前，可用于改善脑缺血性卒中结果的有效治疗方法很少。然而，最近越来越多的证据表明，抑制组蛋白去乙酰化酶 (HDAC) 活性在缺血性卒中的体内和体外模型中发挥了强大的保护作用。评测总结. HDAC 是一种翻译后修饰，受组蛋白乙酰转移酶 (HATS) 和组蛋白脱乙酰酶的负调控。基于功能和 DNA 序列相似性，组蛋白去乙酰化酶 (HDAC) 分为四个不同的亚类 (I-IV)。通过调节被破坏的乙酰化稳态，组蛋白的修饰在翻译后脑缺血事件的发展中起着至关重要的作用。HDAC抑制剂（HDACi）主要通过增强组蛋白和非组蛋白乙酰化水平以及增强基因表达和蛋白质修饰功能发挥神经保护作用。本文回顾了HDAC及其抑制剂，希望找到有意义的治疗靶点。结论. HDAC可能是脑缺血性卒中的新生物学靶点。未来针对 HDAC 的药物开发可能使其成为一种潜在有效的抗脑缺血性卒中药物。